deferasirox has been researched along with lenalidomide in 11 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 3,532 | 725 | 2,850 |
| Protein | Taxonomy | deferasirox (IC50) | lenalidomide (IC50) |
|---|---|---|---|
| Bromodomain-containing protein 4 | Homo sapiens (human) | 5.19 | |
| DNA damage-binding protein 1 | Homo sapiens (human) | 1.5953 | |
| Protein cereblon | Homo sapiens (human) | 1.6572 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Ozawa, K | 1 |
| Ohyashiki, K | 1 |
| Tefferi, A | 1 |
| Miyazaki, Y | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Tohyama, K | 1 |
| Benabderrahmane, M; Bourafai-Aziez, A; Carlier, L; Coadou, G; Jouanne, M; Oulyadi, H; Paysant, H; Poulain, L; Ravault, D; Sebban, M; Sopková-de Oliveira Santos, J; Voisin-Chiret, AS; Weiswald, LB | 1 |
6 review(s) available for deferasirox and lenalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
[MDS].
Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles | 2012 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
5 other study(ies) available for deferasirox and lenalidomide
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles | 2010 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles | 2014 |
Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1.
Topics: Apoptosis Regulatory Proteins; Deferasirox; Drug Repositioning; Lenalidomide; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Myeloid Cell Leukemia Sequence 1 Protein; Oxcarbazepine; Risperidone; Torsemide | 2021 |